XORTX Provides Overview and Update of Key Activities
The following summarizes the advancements made in 2019 to date in XORTX’s three programs:
XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD):
Growing outreach to key polycystic disease physicians and patient advocacy groups to advance the XRx-008 program toward a phase 3 registration trial;
XRX-008 program further validated by evidence of a new mechanism of injury in polycystic kidney disease, this study showed that uric acid and oxalate crystals may play a key role in the initiation of new kidney cysts and accelerating the growth of those cysts as well as in the generation of kidney stones in individuals with ADPKD;
Advanced Orphan Drug Designation (“ODD”) documents for completion of filing with the FDA for XRx-008 for the treatment of progressive kidney disease due to ADPKD;
Introduced Dr. Anjay Rastogi, UCLA to XORTX’s Clinical Advisory Board; and
Initiated and ongoing discussions with pharmaceutical company partners for this program.